Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
The Journal of Clinical Investigation
|
February 5, 2011
A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma
Benjamin Ory, Matthew R Ramsey, Catherine Wilson, et al.
Anti-Cancer Drugs
|
February 2, 2023
The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo
Paul M J McSheehy, Nicole Forster-Gross, Mahmoud El Shemerly, et al.
American Journal of Cancer Research
|
June 9, 2023
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma models
Filippo Spriano, Luca Aresu, Luciano Cascione, et al.
Cancer Research
|
December 4, 2010
The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers
Chuanwei Yang, Tetsu Hayashida, Nicole Forster, et al.
Cancer Discovery
|
January 1, 2013
Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma
Lei He, Kristine Torres-Lockhart, Nicole Forster, et al.
The EMBO Journal
|
May 3, 2008
Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation
Axel Weber, Judith Marquardt, David Elzi, et al.
Expert Opinion on Investigational Drugs
|
October 26, 2021
Derazantinib: an investigational drug for the treatment of cholangiocarcinoma
Stephan Braun, Paul McSheehy, Karine Litherland, et al.
Journal of Medical Genetics
|
October 9, 2014
OTX2 mutations cause autosomal dominant pattern dystrophy of the retinal pigment epithelium
Ajoy Vincent, Nicole Forster, Jason T Maynes, et al.
Frontiers in Oncology
|
August 26, 2024
Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination
Elisa Zanini, Nicole Forster-Gross, Felix Bachmann, et al.
Journal of Medical Genetics
|
May 22, 2023
A model for the return and referral of all clinically significant secondary findings of genomic sequencing
Rita Kodida, Emma Reble, Marc Clausen, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
The Journal of Clinical Investigation
|
February 5, 2011
A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma
Benjamin Ory, Matthew R Ramsey, Catherine Wilson, et al.
Anti-Cancer Drugs
|
February 2, 2023
The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo
Paul M J McSheehy, Nicole Forster-Gross, Mahmoud El Shemerly, et al.
American Journal of Cancer Research
|
June 9, 2023
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma models
Filippo Spriano, Luca Aresu, Luciano Cascione, et al.
Cancer Research
|
December 4, 2010
The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers
Chuanwei Yang, Tetsu Hayashida, Nicole Forster, et al.
Cancer Discovery
|
January 1, 2013
Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma
Lei He, Kristine Torres-Lockhart, Nicole Forster, et al.
The EMBO Journal
|
May 3, 2008
Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation
Axel Weber, Judith Marquardt, David Elzi, et al.
Expert Opinion on Investigational Drugs
|
October 26, 2021
Derazantinib: an investigational drug for the treatment of cholangiocarcinoma
Stephan Braun, Paul McSheehy, Karine Litherland, et al.
Journal of Medical Genetics
|
October 9, 2014
OTX2 mutations cause autosomal dominant pattern dystrophy of the retinal pigment epithelium
Ajoy Vincent, Nicole Forster, Jason T Maynes, et al.
Frontiers in Oncology
|
August 26, 2024
Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination
Elisa Zanini, Nicole Forster-Gross, Felix Bachmann, et al.
Journal of Medical Genetics
|
May 22, 2023
A model for the return and referral of all clinically significant secondary findings of genomic sequencing
Rita Kodida, Emma Reble, Marc Clausen, et al.
Page
of 3